Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
DT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation.
Ainley L, Chavda SJ, Counsell N, Cheesman S, Newrick F, Horder J, Kyriakou C, Papanikolaou X, Sive J, Lee L, Wechalekar A, Mehta A, Popat R, Rabin N, Yong K. Ainley L, et al. Among authors: chavda sj. Br J Haematol. 2021 Feb;192(3):e73-e77. doi: 10.1111/bjh.17248. Epub 2020 Nov 25. Br J Haematol. 2021. PMID: 33236352 Free article. No abstract available.
Multiple myeloma.
Chavda SJ, Yong K. Chavda SJ, et al. Br J Hosp Med (Lond). 2017 Feb 2;78(2):C21-C27. doi: 10.12968/hmed.2017.78.2.C21. Br J Hosp Med (Lond). 2017. PMID: 28165783 Review. No abstract available.
Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival.
Chin M, Sive JI, Allen C, Roddie C, Chavda SJ, Smith D, Blombery P, Jones K, Ryland GL, Popat R, Rismani A, D'Sa S, Rabin N, Gale RE, Yong KL. Chin M, et al. Among authors: chavda sj. Blood Cancer J. 2017 Sep 15;7(9):e610. doi: 10.1038/bcj.2017.76. Blood Cancer J. 2017. PMID: 29016571 Free PMC article. Clinical Trial. No abstract available.
Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4+PD-1+ Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma.
Alrasheed N, Lee L, Ghorani E, Henry JY, Conde L, Chin M, Galas-Filipowicz D, Furness AJS, Chavda SJ, Richards H, De-Silva D, Cohen OC, Patel D, Brooks A, Rodriguez-Justo M, Pule M, Herrero J, Quezada SA, Yong KL. Alrasheed N, et al. Among authors: chavda sj. Clin Cancer Res. 2020 Jul 1;26(13):3443-3454. doi: 10.1158/1078-0432.CCR-19-1714. Epub 2020 Mar 27. Clin Cancer Res. 2020. PMID: 32220887
Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy.
Fox TA, Troy-Barnes E, Kirkwood AA, Chan WY, Day JW, Chavda SJ, Kumar EA, David K, Tomkins O, Sanchez E, Scully M, Khwaja A, Lambert J, Singer M, Roddie C, Morris EC, Yong KL, Thomson KJ, Ardeshna KM. Fox TA, et al. Among authors: chavda sj. Br J Haematol. 2020 Oct;191(2):194-206. doi: 10.1111/bjh.17027. Epub 2020 Aug 12. Br J Haematol. 2020. PMID: 32678948 Free PMC article.
Response to 'Impact of immunosuppression on mortality in critically ill COVID-19 patients'.
Fox TA, Troy-Barnes E, Kirkwood AA, Chan WY, Day JW, Chavda SJ, Kumar EA, David K, Tomkins O, Sanchez E, Scully M, Khwaja A, Lambert J, Singer M, Roddie C, Morris EC, Yong KL, Thomson KJ, Ardeshna KM. Fox TA, et al. Among authors: chavda sj. Br J Haematol. 2020 Nov;191(3):505-506. doi: 10.1111/bjh.17110. Epub 2020 Oct 26. Br J Haematol. 2020. PMID: 33103782 Free article. No abstract available.
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Camilleri M, Cuadrado M, Phillips E, Wilson W, Jenner R, Pang G, Kamora S, Streetly M, Popat R, Bygrave C, Owen R, Cavenagh J, Chapman M, Sive J, Eccersley L, Sheaff M, Benjamin R, Ramasamy K, Cook G, Virchis A, Chavda SJ, Clifton-Hadley L, Scully MA, Yong K. Camilleri M, et al. Among authors: chavda sj. Br J Haematol. 2021 May;193(4):750-760. doi: 10.1111/bjh.17377. Epub 2021 Mar 1. Br J Haematol. 2021. PMID: 33650100 Clinical Trial.
Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma.
Lee L, Alrasheed N, Khandelwal G, Fitzsimons E, Richards H, Wilson W, Chavda SJ, Henry J, Conde L, De Massy MR, Chin M, Galas-Filipowicz D, Herrero J, Chain B, Quezada SA, Yong K. Lee L, et al. Among authors: chavda sj. Front Immunol. 2021 Feb 25;12:618610. doi: 10.3389/fimmu.2021.618610. eCollection 2021. Front Immunol. 2021. PMID: 33717112 Free PMC article.
29 results